DYNE THERAPEUTICS INC

29,81

06-ноября-24 15:59:57

15 мин. задержка

Акции

+1,19

+4,16%

Сегодняшний диапазон

29,31 - 30,43

ISIN

N/A

Источник

NASDAQ

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

09 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

23 сен 2024 08:56:28 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Key Leadership Appointments

03 сен 2024 06:31:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

03 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

29 авг 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

12 авг 2024 17:10:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

24 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

13 июн 2024 16:40:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

30 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

28 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

21 май 2024 20:39:57 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

20 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

20 май 2024 06:30:06 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

19 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 май 2024 16:10:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

27 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

27 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Announces CEO Transition

25 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

13 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

05 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.